Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting

Eloxx Pharmaceuticals, Inc.

CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.
Options granted under 2018 Equity Incentive Plan; exercisable in full as of Oct 16, 2024 regardless of vesting.
New exercise price set to $0.0001, the closing OTC price on the repricing date.
Option repricing approved by Board on Oct 16, 2024; amendment approved by Compensation Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.